{"id":55154,"date":"2023-12-20T10:12:31","date_gmt":"2023-12-20T10:12:31","guid":{"rendered":"https:\/\/medsname.com\/glyxambi-empagliflozin\/"},"modified":"2026-05-01T10:49:12","modified_gmt":"2026-05-01T10:49:12","slug":"glyxambi-empagliflozin","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/glyxambi-empagliflozin\/","title":{"rendered":"Glyxambi (Empagliflozin)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Glyxambi?<\/h3>\n<p style=\"margin:0;\"><strong>Glyxambi<\/strong> \u03b5\u03af\u03bd\u03b1\u03b9 \u03ad\u03bd\u03b1 \u03b4\u03b9\u03c3\u03ba\u03af\u03bf \u03c3\u03c4\u03b1\u03b8\u03b5\u03c1\u03ae\u03c2 \u03b4\u03cc\u03c3\u03b7\u03c2 \u03c0\u03bf\u03c5 \u03c3\u03c5\u03bd\u03b4\u03c5\u03ac\u03b6\u03b5\u03b9 <strong>empagliflozin (SGLT-2 inhibitor)<\/strong> \u03ba\u03b1\u03b9 <strong>linagliptin (DPP-4 inhibitor)<\/strong> (Empagliflozin 10 or 25 mg + Linagliptin 5 mg) used for <strong>\u03b4\u03b9\u03b1\u03b2\u03ae\u03c4\u03b7 \u03c4\u03cd\u03c0\u03bf\u03c5 2<\/strong>. It combines two non-insulinotropic mechanisms: empagliflozin causes the kidneys to excrete glucose in urine (for glycaemic, weight, BP, heart-failure, and kidney benefits), while linagliptin raises incretin hormones to stimulate glucose-dependent insulin release. Expected HbA1c reduction: <strong>1.0&ndash;1.3 points<\/strong> &mdash; more than either component alone. Expected weight loss: 2&ndash;3 kg. <strong>Very low hypoglycaemia risk<\/strong> on its own. Once-daily dosing, with or without food. Main side effects: genital thrush, UTI, and rare DKA (empagliflozin); rare pancreatitis or arthralgia (linagliptin). Avoid in type&nbsp;1 diabetes, DKA, eGFR &lt; 30, and severe hepatic impairment.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 <a href=\"https:\/\/medsbase.com\/el\/reviews\/\">\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd <a href=\"https:\/\/medsbase.com\/el\/medsbase-re-shipment-assurance-policy\/\"><strong>\u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n<h3>\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n<p>\u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n<h2 class=\"wp-block-heading\">What Is Glyxambi?<\/h2>\n<p>Glyxambi is a fixed-dose combination oral antidiabetic tablet containing two active ingredients: <strong>empagliflozin<\/strong> (SGLT-2 inhibitor) and <strong>linagliptin<\/strong> (DPP-4 inhibitor), in strengths of Empagliflozin 10 or 25 mg + Linagliptin 5 mg. Manufactured by Boehringer Ingelheim \/ Eli Lilly; available in packs of 30, 60, 90 or 180 tablets. It is prescribed for adults with type&nbsp;2 diabetes &mdash; typically added to metformin, or initiated in patients with significant hyperglycaemia who would benefit from two non-insulinotropic mechanisms in a single tablet.<\/p>\n<h2 class=\"wp-block-heading\">How Does Glyxambi Work?<\/h2>\n<p>The two components target hyperglycaemia through completely separate pathways &mdash; one insulin-independent, one incretin-based:<\/p>\n<ul>\n<li><strong>Empagliflozin<\/strong> blocks SGLT-2 in the kidney proximal tubule, causing 70&ndash;90&nbsp;g of glucose to be excreted in urine each day. This lowers blood glucose independently of insulin and also reduces weight (2&ndash;3 kg), blood pressure (3&ndash;5 mmHg), heart-failure hospitalisations (EMPEROR trials), and CKD progression (EMPA-KIDNEY).<\/li>\n<li><strong>Linagliptin<\/strong> blocks the enzyme DPP-4, raising levels of the incretin hormones GLP-1 and GIP. This stimulates <em>\u03b3\u03bb\u03c5\u03ba\u03cc\u03b6\u03b1-\u03b5\u03be\u03b1\u03c1\u03c4\u03ce\u03bc\u03b5\u03bd\u03bf<\/em> insulin release and suppresses glucagon &mdash; only when blood glucose is elevated. Linagliptin is unique among DPP-4 inhibitors in needing no renal dose adjustment.<\/li>\n<\/ul>\n<p>Because neither component directly stimulates insulin release in a glucose-independent manner, Glyxambi has a <strong>very low hypoglycaemia risk<\/strong> on its own. Expected HbA1c reduction: <strong>1.0&ndash;1.3 percentage points<\/strong> over either component alone.<\/p>\n<h2 class=\"wp-block-heading\">\u0394\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1 \u03ba\u03b1\u03b9 \u03a7\u03bf\u03c1\u03ae\u03b3\u03b7\u03c3\u03b7<\/h2>\n<p><strong>\u03a3\u03c5\u03bd\u03ae\u03b8\u03b7\u03c2 \u03b4\u03cc\u03c3\u03b7:<\/strong> one tablet once daily in the morning, with or without food. The starting strength depends on prior therapy and glycaemic target.<\/p>\n<ul>\n<li><strong>\u03a7\u03ac\u03c3\u03b1\u03c4\u03b5 \u03bc\u03b9\u03b1 \u03b4\u03cc\u03c3\u03b7;<\/strong> Take as soon as you remember if it is within 12 hours; otherwise skip.<\/li>\n<li><strong>\u03a7\u03bf\u03c1\u03ae\u03b3\u03b7\u03c3\u03b7 \u03c3\u03b5 \u03bd\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae \u03b4\u03c5\u03c3\u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1:<\/strong> empagliflozin is limited to eGFR &gt; 20 for HF\/CKD indications (&gt; 30 for glycaemic control); linagliptin needs no renal dose adjustment. The combination is typically avoided if eGFR &lt; 30.<\/li>\n<li><strong>Sick-day rules:<\/strong> pause during acute illness with vomiting, diarrhoea, or reduced oral intake (risk of euglycaemic DKA and AKI). Restart when eating and drinking normally.<\/li>\n<li><strong>Do not start<\/strong> within 48 hours of major surgery or IV contrast.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n<p><strong>Common (mostly from the empagliflozin component):<\/strong><\/p>\n<ul>\n<li>Genital mycotic infections (thrush) &mdash; up to 10% of users<\/li>\n<li>Urinary tract infections<\/li>\n<li>Polyuria, mild dehydration, postural dizziness in the first 2 weeks<\/li>\n<li>Modest LDL-cholesterol rise<\/li>\n<\/ul>\n<p><strong>From the linagliptin component:<\/strong><\/p>\n<ul>\n<li>Nasopharyngitis, headache, mild GI upset<\/li>\n<\/ul>\n<p><strong>\u03a3\u03c0\u03ac\u03bd\u03b9\u03b1 \u03b1\u03bb\u03bb\u03ac \u03c3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03ac:<\/strong><\/p>\n<ul>\n<li><strong>Diabetic ketoacidosis (DKA)<\/strong> &mdash; rare; can occur at near-normal blood glucose (&ldquo;euglycaemic DKA&rdquo;). Symptoms: nausea, vomiting, abdominal pain, deep breathing. Stop the drug and seek urgent care.<\/li>\n<li><strong>Volume depletion, AKI<\/strong> &mdash; higher risk on diuretics or with acute illness<\/li>\n<li><strong>Acute pancreatitis, severe arthralgia, bullous pemphigoid<\/strong> &mdash; rare DPP-4 class effects<\/li>\n<li><strong>Fournier&rsquo;s gangrene<\/strong> &mdash; extremely rare but serious<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03a6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd<\/h2>\n<ul>\n<li><strong>Diuretics (loop and thiazide)<\/strong> &mdash; additive volume loss; consider diuretic dose reduction.<\/li>\n<li><strong>Insulin, sulfonylureas, meglitinides<\/strong> &mdash; additive glucose-lowering; may need dose reduction to avoid hypoglycaemia.<\/li>\n<li><strong>\u03a1\u03b9\u03c6\u03b1\u03bc\u03c0\u03b9\u03ba\u03af\u03bd\u03b7<\/strong> &mdash; reduces levels of both components.<\/li>\n<li><strong>\u0391\u03bd\u03c4\u03b9\u03c5\u03c0\u03b5\u03c1\u03c4\u03b1\u03c3\u03b9\u03ba\u03ac<\/strong> &mdash; additive BP-lowering.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Who Should Not Take Glyxambi?<\/h2>\n<ul>\n<li>\u03a3\u03b1\u03ba\u03c7\u03b1\u03c1\u03ce\u03b4\u03b7\u03c2 \u03b4\u03b9\u03b1\u03b2\u03ae\u03c4\u03b7\u03c2 \u03c4\u03cd\u03c0\u03bf\u03c5 1<\/li>\n<li>Diabetic ketoacidosis &mdash; current or recent history<\/li>\n<li>\u03a3\u03bf\u03b2\u03b1\u03c1\u03ae \u03bd\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae \u03b4\u03c5\u03c3\u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1 (eGFR &lt; 30)<\/li>\n<li>Severe volume depletion or hypotension<\/li>\n<li>\u03a3\u03bf\u03b2\u03b1\u03c1\u03ae \u03b7\u03c0\u03b1\u03c4\u03b9\u03ba\u03ae \u03b4\u03c5\u03c3\u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1<\/li>\n<li>\u0399\u03c3\u03c4\u03bf\u03c1\u03b9\u03ba\u03cc \u03c0\u03b1\u03b3\u03ba\u03c1\u03b5\u03b1\u03c4\u03af\u03c4\u03b9\u03b4\u03b1\u03c2 (\u03c3\u03c5\u03b3\u03b3\u03b5\u03bd\u03b9\u03ba\u03cc)<\/li>\n<li>\u0393\u03bd\u03c9\u03c3\u03c4\u03ae \u03c5\u03c0\u03b5\u03c1\u03b5\u03c5\u03b1\u03b9\u03c3\u03b8\u03b7\u03c3\u03af\u03b1 \u03c3\u03b5 \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b1 \u03c3\u03c5\u03c3\u03c4\u03b1\u03c4\u03b9\u03ba\u03ac<\/li>\n<li>\u0395\u03b3\u03ba\u03c5\u03bc\u03bf\u03c3\u03cd\u03bd\u03b7 \u03ba\u03b1\u03b9 \u03b8\u03b7\u03bb\u03b1\u03c3\u03bc\u03cc\u03c2<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u0391\u03c0\u03bf\u03b8\u03ae\u03ba\u03b5\u03c5\u03c3\u03b7<\/h2>\n<p>Store Glyxambi below 30&deg;C in a dry place. Keep out of reach of children.<\/p>\n<h2 id=\"faqs\">\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u0395\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n<h3 class=\"wp-block-heading\">Why combine an SGLT-2 inhibitor and a DPP-4 inhibitor in one tablet?<\/h3>\n<p>The two classes work by completely different mechanisms that do not overlap, so the HbA1c reduction of the combination is additive (1.0&ndash;1.3 points) rather than redundant. Both are weight-neutral to weight-favourable, and both have a very low hypoglycaemia risk, making the combination a good fit for patients who need additional glucose control without adding insulin or sulfonylurea risk.<\/p>\n<h3 class=\"wp-block-heading\">Will Glyxambi help me lose weight?<\/h3>\n<p>Yes, modestly &mdash; typically 2&ndash;3 kg over 6&ndash;12 months. The weight loss comes from the empagliflozin component (urinary glucose excretion). Linagliptin is weight-neutral.<\/p>\n<h3 class=\"wp-block-heading\">Does Glyxambi protect my heart and kidneys?<\/h3>\n<p>The empagliflozin component has strong evidence from EMPA-REG, EMPEROR-Reduced, EMPEROR-Preserved, and EMPA-KIDNEY trials for cardiovascular, heart failure, and kidney protection. Linagliptin is cardiovascular-neutral in CARMELINA. So the combination retains the empagliflozin cardio-renal benefits.<\/p>\n<h3 class=\"wp-block-heading\">Will Glyxambi cause low blood sugar?<\/h3>\n<p>On its own, very rarely. Neither component stimulates insulin release in a glucose-independent manner. Hypoglycaemia becomes a concern when Glyxambi is combined with a sulfonylurea, meglitinide, or insulin.<\/p>\n<h3 class=\"wp-block-heading\">What about thrush?<\/h3>\n<p>Genital thrush is the most common side effect (up to 10% of users, mostly women). It is usually mild and easily treated. Most patients do not need to stop Glyxambi.<\/p>\n<h3 class=\"wp-block-heading\">Where can I buy Glyxambi online?<\/h3>\n<p>You can order Glyxambi (Empagliflozin 10 or 25 mg + Linagliptin 5 mg) from MedsBase in packs of 30, 60, 90 or 180 tablets. We ship worldwide, with discreet packaging and genuine WHO-GMP certified manufacturer stock.<\/p>\n<h2 class=\"wp-block-heading\">\u03a3\u03c7\u03b5\u03c4\u03b9\u03ba\u03ac \u03a6\u03ac\u03c1\u03bc\u03b1\u03ba\u03b1 \u03b3\u03b9\u03b1 \u0394\u03b9\u03b1\u03b2\u03ae\u03c4\u03b7<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/el\/jardiance-empagliflozin\/\">Jardiance &mdash; Empagliflozin monotherapy<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/trajenta\/\">Trajenta \u2014 \u039c\u03bf\u03bd\u03bf\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03bc\u03b5 Linagliptin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/forxiga-dapagliflozin\/\">Forxiga \u2014 Dapagliflozin (\u03b5\u03bd\u03b1\u03bb\u03bb\u03b1\u03ba\u03c4\u03b9\u03ba\u03ae SGLT-2)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/januvia\/\">Januvia &mdash; Sitagliptin (DPP-4 alternative)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/trajenta-duo\/\">Trajenta Duo &mdash; Linagliptin + Metformin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/glycomet-sr\/\">Glycomet SR \u2014 \u039c\u03b5\u03c4\u03c6\u03bf\u03c1\u03bc\u03af\u03bd\u03b7 \u03c0\u03b1\u03c1\u03b1\u03c4\u03b5\u03c4\u03b1\u03bc\u03ad\u03bd\u03b7\u03c2 \u03b1\u03c0\u03bf\u03b4\u03ad\u03c3\u03bc\u03b5\u03c5\u03c3\u03b7\u03c2<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/diabetes-medication\/\"><strong>\u03a0\u03b5\u03c1\u03b9\u03ae\u03b3\u03b7\u03c3\u03b7 \u03cc\u03bb\u03c9\u03bd \u03c4\u03c9\u03bd \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd \u03b3\u03b9\u03b1 \u0394\u03b9\u03b1\u03b2\u03ae\u03c4\u03b7<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 \u0399\u03b1\u03c4\u03c1\u03b9\u03ba\u03ae \u0391\u03c0\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u0395\u03c5\u03b8\u03cd\u03bd\u03b7\u03c2.<\/strong> This page is for informational purposes only and does not replace medical advice from a qualified healthcare professional. SGLT-2 inhibitor combinations carry a small but serious risk of euglycaemic DKA &mdash; always use under medical guidance with sick-day rules in place.<\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">\u03a3\u03c7\u03b5\u03c4\u03b9\u03ba\u03ad\u03c2 \u0395\u03bd\u03b1\u03bb\u03bb\u03b1\u03ba\u03c4\u03b9\u03ba\u03ad\u03c2<\/h3>\n<p>\u0386\u03bb\u03bb\u03b1 \u03c0\u03c1\u03bf\u03ca\u03cc\u03bd\u03c4\u03b1 \u03c3\u03b5 <strong>\u03a7\u03c1\u03cc\u03bd\u03b9\u03b5\u03c2 \u03a0\u03b1\u03b8\u03ae\u03c3\u03b5\u03b9\u03c2<\/strong> \u03c0\u03bf\u03c5 \u03bf\u03b9 \u03c0\u03b5\u03bb\u03ac\u03c4\u03b5\u03c2 \u03b5\u03be\u03b5\u03c4\u03ac\u03b6\u03bf\u03c5\u03bd \u03b5\u03c0\u03af\u03c3\u03b7\u03c2:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/el\/symbicort-turbohaler\/\">Symbicort Turbohaler<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/trivastal-la\/\">Trivastal LA<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/lefuheal\/\">Lefuheal<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/ketanov-injection\/\">Ketanov Injection<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/hydrosar\/\">Hydrosar<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 \u0395\u03bb\u03ad\u03b3\u03c7\u03b5\u03b9 \u03c4\u03b1 \u03b5\u03c0\u03af\u03c0\u03b5\u03b4\u03b1 \u03c3\u03b1\u03ba\u03c7\u03ac\u03c1\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b1\u03af\u03bc\u03b1<br \/>\n\u2705 \u039c\u03b5\u03b9\u03ce\u03bd\u03b5\u03b9 \u03c4\u03bf\u03bd \u03ba\u03af\u03bd\u03b4\u03c5\u03bd\u03bf \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ae\u03c2 \u03bd\u03cc\u03c3\u03bf\u03c5<br \/>\n\u2705 Promotes <a href=\"https:\/\/medsbase.com\/el\/rybelsus-an-effective-solution-for-weight-loss\/\" title=\"Rybelsus an Effective Solution for Weight Loss\">(\u03b5\u03af\u03bd\u03b1\u03b9 \u03c3\u03c5\u03c3\u03c4\u03b1\u03c4\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b5\u03b3\u03ba\u03b5\u03ba\u03c1\u03b9\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd FDA \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03b3\u03b9\u03b1 \u03c4\u03b7\u03bd \u03c0\u03b1\u03c7\u03c5\u03c3\u03b1\u03c1\u03ba\u03af\u03b1 Qsymia\u00ae \u03bc\u03b1\u03b6\u03af \u03bc\u03b5 \u03c6\u03b5\u03bd\u03c4\u03b5\u03c1\u03bc\u03af\u03bd\u03b7).<\/a><br \/>\n\u2705 <a href=\"https:\/\/medsbase.com\/el\/how-to-lower-your-blood-pressure\/\" title=\"\u03a0\u03ce\u03c2 \u03bd\u03b1 \u03bc\u03b5\u03b9\u03ce\u03c3\u03b5\u03c4\u03b5 \u03c4\u03b7\u03bd \u03c0\u03af\u03b5\u03c3\u03b7 \u03c4\u03bf\u03c5 \u03b1\u03af\u03bc\u03b1\u03c4\u03cc\u03c2 \u03c3\u03b1\u03c2\">Lowers blood pressure<\/a><br \/>\n\u2705 Improves kidney function<\/p>\n<p><span style=\"color: #999999;\">Glyxambi contains Empagliflozin &amp; Linagliptin<\/span><\/p>","protected":false},"featured_media":55155,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3230,3231],"product_tag":[3870,3872,3278],"class_list":{"0":"post-55154","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-diabetes","9":"product_cat-diabetes-medication","10":"product_tag-empagliflozin","11":"product_tag-glyxambi","12":"product_tag-linagliptin","14":"first","15":"instock","16":"shipping-taxable","17":"purchasable","18":"product-type-variable","19":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product\/55154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/comments?post=55154"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media\/55155"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media?parent=55154"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_brand?post=55154"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_cat?post=55154"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_tag?post=55154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}